Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease
22 août 2023 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the National Institute of Aging (NIA), has...
Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362
28 juin 2023 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., June 28, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., today announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal...
Neuronascent Releases Further Positive Results of NNI-362 in A Randomized Phase 1a Trial for Alzheimer’s Disease
30 mars 2022 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., March 30, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc., is a clinical-stage pharmaceutical company discovering and developing novel regenerative therapies for age-related brain...
Neuronascent Announces Publication of Pre-clinical Results of Alzheimer’s Disease Clinical Candidate, NNI-362 in SCR&T Journal
20 janv. 2021 06h00 HE
|
Neuronascent, Inc.
CLARKSVILLE, Md., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced the publication of results of their novel...
Neuronascent Announces FDA Clearance of IND Application for NNI-362 an Aging Therapy to Treat Alzheimer's Disease
07 mai 2019 05h00 HE
|
Neuronascent, Inc.
CLARKSVILLE, Md., May 07, 2019 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has...
Neuronascent Awarded $2.25 Million NIH Grant to Develop a Regenerative Therapeutic for Alzheimer’s Disease
19 sept. 2018 06h00 HE
|
Neuronascent, Inc.
CLARKSVILLE, Md., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the National Institute on Aging (NIA), part of...
Neuronascent Granted Composition of Matter Patent in Europe for Oral Neuron Regenerative Technology
14 nov. 2017 07h00 HE
|
Neuronascent, Inc.
CLARKSVILLE, Md., Nov. 14, 2017 (GLOBE NEWSWIRE) -- Neuronascent, Inc. (www.neuronascent.com), a biopharmaceutical company focused on oral therapeutics to promote neuron regeneration, today...
Neuronascent Announces Third US Patent Issued Covering Therapeutics for Neurodegenerative and Neuropsychiatric Disorders
24 janv. 2017 06h00 HE
|
Neuronascent, Inc.
CLARKSVILLE, MD--(Marketwired - January 24, 2017) - Neuronascent's U.S. Patent No. 9,539,261, which issued on January 10, 2017, claims methods of stimulating neurogenesis and/or inhibiting neuronal...